REED STEVEN G,VAN HOEVEN NEAL,CLEGG CHRISTOPHER H.
申请号：
NZ60221711
公开号：
NZ602217A
申请日:
2011.03.10
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
Disclosed is the use of a pharmaceutical composition for the manufacture of a vaccine for immunising a subject in need thereof against an influenza virus by way of a single injection, the composition comprising: a) a recombinant hemagglutinin (rHA) from an influenza virus, and b) an adjuvant, wherein the adjuvant comprises a disaccharide having a reducing and a non-reducing terminus each independently selected from glucosyl and amino substituted glucosyl, where a carbon at a 1 position of the non-reducing terminus is linked through either an ether (-O-) or amino (-NH-) group to a carbon at a 6&rsquo position of the reducing terminus, the disaccharide being bonded to a phosphate group through a 4&rsquo carbon of the non-reducing terminus and to a plurality of lipid groups through amide (-NH-C(O)-) and/or ester (-O-C(O)-) linkages, where the carbonyl (-C(O)-) group of the ester or amide linkage is directly linked to the lipid group, and each lipid group comprises at least 8 carbons and wherein the composition is dosage sparing, and wherein the amount of rHA per dose unit is in the range of 0.1&mug to 15&mug.
